Vandetanib

From Self-sufficiency
Jump to: navigation, search
Vandetanib
File:Vandetanib.svg
Systematic (IUPAC) name
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Clinical data
Routes of
administration		 Oral
Pharmacokinetic data
Biological half-life 5 days (mean)
Identifiers
CAS Number 443913-73-3
ATC code none
PubChem CID 3081361
Chemical data
Formula C22H24BrFN4O2
Molar mass 475.354 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR)[1]. It is a tyrosine kinase inhibitor.

Drug has a third target: inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer


Current status

Vandetanib is being developed by AstraZeneca. It is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. There have been some promising results from a phase III trial with docetaxel[2]. There have also been ambivalent results when used with pemetrexed[3] Another trial with docetaxel was recruiting in July 2009[4]. AstraZeneca withdrew regulatory submissions for Zactima in October 2009 after trials showed no benefit when the drug was administered alongside chemotherapy [5].

External links

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
CI monoclonal antibodies ("-mab")
Others for solid tumors
Tyrosine kinase inhibitors ("-nib")
Other
Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
  1. ↑ http://nci.nih.gov/Templates/drugdictionary.aspx?CdrID=269177
  2. ↑ http://www.sciencedaily.com/releases/2009/06/090601092237.htm "Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer" June 2009
  3. ↑ http://www.medpagetoday.com/MeetingCoverage/IASLC/15396 "IASLC: Vandetanib Fails to Improve NSCLC Outcomes with Pemetrexed" Aug 2009
  4. ↑ http://clinicaltrials.gov/ct2/show/NCT00687297
  5. ↑ http://www.guardian.co.uk/business/marketforceslive/2009/oct/28/astrazeneca-glaxosmithkline "AstraZeneca drops after it withdraws submissions for cancer drug"
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Vandetanib&oldid=23020"